These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8782740)

  • 1. Structure of HLA molecules and immunosuppressive effects of HLA derived peptides.
    Krensky AM; Clayberger C
    Int Rev Immunol; 1996; 13(3):173-85. PubMed ID: 8782740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence variability analysis of human class I and class II MHC molecules: functional and structural correlates of amino acid polymorphisms.
    Reche PA; Reinherz EL
    J Mol Biol; 2003 Aug; 331(3):623-41. PubMed ID: 12899833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-derived peptides as novel immunosuppressives.
    Krensky AM
    Pediatr Res; 1995 Sep; 38(3):275-9. PubMed ID: 7494646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward the prediction of class I and II mouse major histocompatibility complex-peptide-binding affinity: in silico bioinformatic step-by-step guide using quantitative structure-activity relationships.
    Hattotuwagama CK; Doytchinova IA; Flower DR
    Methods Mol Biol; 2007; 409():227-45. PubMed ID: 18450004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the structure of naturally processed peptides bound by class I and class II major histocompatibility complex molecules.
    Appella E; Padlan EA; Hunt DF
    EXS; 1995; 73():105-19. PubMed ID: 7579970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-derived peptides which inhibit T cell function bind to members of the heat-shock protein 70 family.
    Nossner E; Goldberg JE; Naftzger C; Lyu SC; Clayberger C; Krensky AM
    J Exp Med; 1996 Feb; 183(2):339-48. PubMed ID: 8627147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles.
    Pavlos R; McKinnon EJ; Ostrov DA; Peters B; Buus S; Koelle D; Chopra A; Schutte R; Rive C; Redwood A; Restrepo S; Bracey A; Kaever T; Myers P; Speers E; Malaker SA; Shabanowitz J; Jing Y; Gaudieri S; Hunt DF; Carrington M; Haas DW; Mallal S; Phillips EJ
    Sci Rep; 2017 Aug; 7(1):8653. PubMed ID: 28819312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptides bound to major histocompatibility complex molecules.
    Maffei A; Harris PE
    Peptides; 1998; 19(1):179-98. PubMed ID: 9437752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biochemistry and cell biology of antigen processing and presentation.
    Germain RN; Margulies DH
    Annu Rev Immunol; 1993; 11():403-50. PubMed ID: 8476568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell antigen receptor recognition of antigen-presenting molecules.
    Rossjohn J; Gras S; Miles JJ; Turner SJ; Godfrey DI; McCluskey J
    Annu Rev Immunol; 2015; 33():169-200. PubMed ID: 25493333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
    Carstens C; Newman DK; Bohlen H; König A; Koch N
    Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism and evolution of HLA class I and II genes and molecules.
    Little AM; Parham P
    Rev Immunogenet; 1999; 1(1):105-23. PubMed ID: 11256568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A structural basis for antigen presentation by the MHC class Ib molecule, Qa-1b.
    Zeng L; Sullivan LC; Vivian JP; Walpole NG; Harpur CM; Rossjohn J; Clements CS; Brooks AG
    J Immunol; 2012 Jan; 188(1):302-10. PubMed ID: 22131332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rules for peptide binding to MHC class II molecules.
    Sinigaglia F; Hammer J
    APMIS; 1994 Apr; 102(4):241-8. PubMed ID: 7516671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of naturally processed peptides eluted from HLA DRB1*0402 and *0404.
    Hayden JB; McCormack AL; Yates JR; Davey MP
    J Neurosci Res; 1996 Sep; 45(6):795-802. PubMed ID: 8892091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of the non-classical MHC proteins HLA-DM and HLA-DO on loading of MHC class II molecules.
    Kropshofer H; Hämmerling GJ; Vogt AB
    Immunol Rev; 1999 Dec; 172():267-78. PubMed ID: 10631952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural principles of MHC class II antigen presentation.
    Nelson CA; Fremont DH
    Rev Immunogenet; 1999; 1(1):47-59. PubMed ID: 11256572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulation by HLA class I-derived peptides.
    Krensky AM; Clayberger C
    Transplant Proc; 1996 Dec; 28(6):3026-8. PubMed ID: 8962174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of residues in the class II-associated Ii peptide (CLIP) region of invariant chain that affect efficiency of MHC class II-mediated antigen presentation in an allele-dependent manner.
    Gautam AM; Yang M; Milburn PJ; Baker R; Bhatnagar A; McCluskey J; Boston T
    J Immunol; 1997 Sep; 159(6):2782-8. PubMed ID: 9300699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
    Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
    Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.